menu
    • menu

    Find Netupitant manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 7
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    9

    API Suppliers

    4

    USDMF

    0

    CEP/COS

    0

    JDMF

    1

    EU WC

    1

    KDMF

    2

    NDC API

    0

    VMF

    5

    Listed Suppliers

    3INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    16

    FDF Dossiers

    1

    FDA Orange Book

    10

    Europe

    1

    Canada

    2

    Australia

    1

    South Africa

    1

    Listed Dossiers

    7PROSPECTS

    22DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    112RELATED EXCIPIENT COMPANIES

    159EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    12

    US Patents

    0

    US Exclusivities

    3

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    4,949,593

    Annual Reports

    NA

    Regulatory FDF Prices

    MARKET PLACE

    4

    API

    1

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    19

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 290297-26-6, 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide, 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide, Ro-67-3189, Ro-673189000, Ro 67-3189/000
    Molecular Formula
    C30H32F6N4O
    Molecular Weight
    578.6  g/mol
    InChI Key
    WAXQNWCZJDTGBU-UHFFFAOYSA-N
    FDA UNII
    7732P08TIR
    Netupitant
    Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV). SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK-receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema.
    Netupitant is a Substance P/Neurokinin-1 Receptor Antagonist. The mechanism of action of netupitant is as a Neurokinin 1 Antagonist, and Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
    1 2D Structure

    Netupitant

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
    2.1.2 InChI
    InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
    2.1.3 InChI Key
    WAXQNWCZJDTGBU-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
    2.2 Other Identifiers
    2.2.1 UNII
    7732P08TIR
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamide

    2. 2-(3,5-bis(trifluoromethyl)phenyl)-n-methyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamide

    3. Benzeneacetamide, N, Alpha, Alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

    4. Benzeneacetamide, N, Alpha,alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-, Hydrochloride (1:2)

    5. Netupitant Dihydrochloride

    6. Netupitant Hydrochloride

    7. Ro 67-3189 000

    8. Ro 673189000

    9. Ro-67-3189

    10. Ro-67-3189 000

    11. Ro-673189000

    2.3.2 Depositor-Supplied Synonyms

    1. 290297-26-6

    2. 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide

    3. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide

    4. Ro-67-3189

    5. Ro-673189000

    6. Ro 67-3189/000

    7. Chembl206253

    8. Chebi:85155

    9. 7732p08tir

    10. Cid 6451149

    11. Ro 67-31898/000

    12. Benzeneacetamide, N,alpha,alpha-trimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-

    13. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamide

    14. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide

    15. 2-[3,5-bis(trifluoromethyl)phenyl]-~{n},2-dimethyl-~{n}-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide

    16. Netupitant [usan]

    17. Netupitant [usan:inn]

    18. Unii-7732p08tir

    19. Benzeneacetamide, N,alpha,alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

    20. Cid6451149

    21. Netupitant [mi]

    22. Netupitant [inn]

    23. Netupitant (usan/inn)

    24. Netupitant [vandf]

    25. Netupitant [who-dd]

    26. Schembl445804

    27. Gtpl5742

    28. Netupitant(cid-6451149)

    29. Netupitant [orange Book]

    30. Dtxsid50183271

    31. Glxc-15009

    32. Hms3887e19

    33. Bcp08751

    34. Ex-a2747

    35. Bdbm50178574

    36. Mfcd25976831

    37. S4654

    38. Zinc11681563

    39. Akos027251056

    40. Ccg-270121

    41. Cs-3337

    42. Db09048

    43. Sb18973

    44. Cid-6451149

    45. Ncgc00390569-01

    46. 2-(3,5-bis(trifluoromethyl)phenyl)-n-methyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamide

    47. Ac-29232

    48. As-10239

    49. Hy-16346

    50. Ro 67-31898

    51. Akynzeo Capsule Component Netupitant

    52. Netupitant Component Akynzeo Capsule

    53. Ft-0699740

    54. A14428

    55. D05152

    56. Ro-67-3189/000

    57. Q19598139

    58. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide, Aldrichcpr

    59. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1yl)-4-(o-tolyl)pyridin-3yl)propanamide

    60. 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide

    61. 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide

    62. Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

    63. Gaw

    64. N,alpha,alpha-trimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-benzeneacetamide

    2.4 Create Date
    2006-04-29
    3 Chemical and Physical Properties
    Molecular Weight 578.6 g/mol
    Molecular Formula C30H32F6N4O
    XLogP36.8
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count5
    Exact Mass578.24803063 g/mol
    Monoisotopic Mass578.24803063 g/mol
    Topological Polar Surface Area39.7 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity865
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Active Moiety
    NETUPITANT
    5.1.2 FDA UNII
    7732P08TIR
    5.1.3 Pharmacological Classes
    Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors
    5.2 Absorption, Distribution and Excretion

    Absorption

    Upon oral administration of a single dose of netupitant, netupitant started to be measurable in plasma between 15 minutes and 3 hours after dosing. Plasma concentrations reached Cmax in approximately 5 hours. There was a greater than dose-proportional increase in the systemic exposure with the dose increase from 10 mg to 300 mg and a dose-proportional increase in systemic exposure with a dose increase from 300 mg to 450 mg.

    Route of Elimination

    Primarily fecal.

    Volume of Distribution

    In cancer patients, Vz/F: 1982 906 L (mean SD).

    Clearance

    Estimated systemic clearance of 20.3 9.2 L/h (mean SD).

    5.3 Metabolism/Metabolites

    Once absorbed, netupitant is extensively metabolized to form three major metabolites: desmethyl derivative, M1; N-oxide derivative, M2; and OH-methyl derivative, M3. Metabolism is mediated primarily by CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. Metabolites M1, M2 and M3 were shown to bind to the substance P/neurokinin 1 (NK1) receptor.

    5.4 Biological Half-Life

    96 hours with CV% of 61.

    5.5 Mechanism of Action

    Delayed emesis (vomiting) has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Granulation

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Topical

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 290297-26-6 / Netupitant API manufacturers, exporters & distributors?

    Netupitant manufacturers, exporters & distributors 1

    60

    PharmaCompass offers a list of Netupitant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Netupitant manufacturer or Netupitant supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Netupitant manufacturer or Netupitant supplier.

    API | Excipient name

    Netupitant

    Synonyms

    290297-26-6, 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide, 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide, Ro-67-3189, Ro-673189000, Ro 67-3189/000

    Cas Number

    290297-26-6

    Unique Ingredient Identifier (UNII)

    7732P08TIR

    About Netupitant

    Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV). SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK-receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema.

    Netupitan Manufacturers

    A Netupitan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Netupitan, including repackagers and relabelers. The FDA regulates Netupitan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Netupitan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Netupitan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Netupitan Suppliers

    A Netupitan supplier is an individual or a company that provides Netupitan active pharmaceutical ingredient (API) or Netupitan finished formulations upon request. The Netupitan suppliers may include Netupitan API manufacturers, exporters, distributors and traders.

    click here to find a list of Netupitan suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Netupitan USDMF

    A Netupitan DMF (Drug Master File) is a document detailing the whole manufacturing process of Netupitan active pharmaceutical ingredient (API) in detail. Different forms of Netupitan DMFs exist exist since differing nations have different regulations, such as Netupitan USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Netupitan DMF submitted to regulatory agencies in the US is known as a USDMF. Netupitan USDMF includes data on Netupitan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Netupitan USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Netupitan suppliers with USDMF on PharmaCompass.

    Netupitan KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Netupitan Drug Master File in Korea (Netupitan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Netupitan. The MFDS reviews the Netupitan KDMF as part of the drug registration process and uses the information provided in the Netupitan KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Netupitan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Netupitan API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Netupitan suppliers with KDMF on PharmaCompass.

    Netupitan WC

    A Netupitan written confirmation (Netupitan WC) is an official document issued by a regulatory agency to a Netupitan manufacturer, verifying that the manufacturing facility of a Netupitan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Netupitan APIs or Netupitan finished pharmaceutical products to another nation, regulatory agencies frequently require a Netupitan WC (written confirmation) as part of the regulatory process.

    click here to find a list of Netupitan suppliers with Written Confirmation (WC) on PharmaCompass.

    Netupitan NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Netupitan as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Netupitan API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Netupitan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Netupitan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Netupitan NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Netupitan suppliers with NDC on PharmaCompass.

    Netupitan GMP

    Netupitan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Netupitan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Netupitan GMP manufacturer or Netupitan GMP API supplier for your needs.

    Netupitan CoA

    A Netupitan CoA (Certificate of Analysis) is a formal document that attests to Netupitan's compliance with Netupitan specifications and serves as a tool for batch-level quality control.

    Netupitan CoA mostly includes findings from lab analyses of a specific batch. For each Netupitan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Netupitan may be tested according to a variety of international standards, such as European Pharmacopoeia (Netupitan EP), Netupitan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Netupitan USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search